Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Sandoz launches Glatopa in US market ...
Home  »  Community News  »  Sandoz launches Glat...
Sandoz launches Glatopa in US market to treat multiple sclerosis
Pharma News
, , , , , , , ,

Sandoz, a Novartis company, has launched Glatopa in US markets. Glatopa is the first generic version of Teva’s Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.
“Sandoz, together with Momenta, is proud to announce the US market launch of a fully substitutable generic version of this important therapy, following FDA approval” said Peter Goldschmidt, president of Sandoz US.

MS is a debilitating disease affecting about half a million individuals in the US alone; only half of those diagnosed are currently treated.

Glatopa, developed in collaboration with Momenta and produced entirely in the US, is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.

The Sandoz service offering will include financial assistance to qualified patients, personalized injection training and 24-hour access to nurses for non-clinical questions.

Leave a reply

You must be logged in to post a comment.